Drug Profile
Research programme: CNS disease therapeutics - Bristol-Myers Squibb
Alternative Names: Disease activated CNS therapeutics; pH-activated CNS therapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator NeurOp
- Developer Bristol-Myers Squibb; NeurOp
- Class Small molecules
- Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators; NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cerebral ischaemia; Major depressive disorder; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cerebral-ischaemia(Prevention) in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder(Treatment-resistant) in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (Parenteral)